Evidence map›Paper›PMID 40280984›Full record

ArticleCell death & disease2025

Correction to: Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways.

Yang Li, Zhichao Xi, Xiaoqiong Chen, Shuangfan Cai, Chen Liang, Zhen Wang, Yingyi Li, Hongsheng Tan, Yuanzhi Lao, Hongxi Xu

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Yang Li *School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
Zhichao Xi *School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
Xiaoqiong ChenSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
Shuangfan CaiSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
Chen LiangCancer Research Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhen WangCancer Research Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Yingyi LiCancer Research Institute, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Hongsheng TanSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China.
Yuanzhi LaoSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China. laurence_ylao@163.com.ORCID http://orcid.org/0000-0002-7803-4484
Hongxi XuSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, P. R. China. xuhongxi88@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40280984
PMCPMC12032033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.